The tissue transglutaminase IgA test, usually shortened to tTG-IgA, is the main blood test used to screen for celiac disease. It detects an autoimmune antibody that commonly rises when a genetically susceptible person eats gluten and develops immune injury in the small intestine. A positive result can make celiac disease much more likely, especially when the level is many times above the laboratory’s upper limit of normal. However, the result is not interpreted in isolation. The amount of gluten being eaten, the total IgA level, symptoms, age, medical history, assay used, and sometimes an intestinal biopsy all affect what the result means. A negative test also does not exclude every case. Testing is most accurate before a gluten-free diet begins, so changing the diet too early can complicate or delay diagnosis. Understanding the full testing pathway helps prevent both missed celiac disease and unnecessary lifelong dietary restriction.
- tTG-IgA is the preferred first-line celiac disease blood test for most people who produce normal amounts of IgA.
- Testing should usually be performed while the person is still eating gluten.
- Results must be judged against the specific laboratory’s upper limit of normal, not a universal number.
- A positive tTG-IgA result supports celiac disease but often requires specialist confirmation.
- A negative result may be unreliable when total IgA is low, gluten intake is limited, or clinical suspicion remains high.
Table of Contents
- What the tTG-IgA Test Measures
- Who Should Be Tested
- How to Prepare for Testing
- Understanding tTG-IgA Results
- Total IgA and Related Antibody Tests
- What Happens After a Positive Result
- False-Negative, False-Positive, and Conflicting Results
- Follow-Up After Celiac Disease Is Diagnosed
What the tTG-IgA Test Measures
Tissue transglutaminase, also called transglutaminase 2 or TG2, is an enzyme found throughout the body. In celiac disease, gluten-derived proteins reach the small-intestinal lining and are modified by this enzyme. In people with the appropriate genetic susceptibility, the immune system can then produce IgA antibodies directed against tissue transglutaminase. The tTG-IgA blood test measures those antibodies.
This makes tTG-IgA an autoimmune serology test rather than a direct measurement of gluten, intestinal absorption, or physical damage. It does not show how much gluten someone ate, identify a food allergy, or provide a picture of the intestinal lining. It also does not measure total IgA. A separate total IgA test is often needed to establish whether the person can produce enough IgA for an IgA-based celiac test to be dependable.
Most laboratories use an automated immunoassay, commonly an enzyme-linked immunosorbent assay or a chemiluminescent method. The laboratory exposes the patient’s serum to tissue transglutaminase antigen and reports whether binding IgA antibodies are present. Results may be expressed in units per milliliter, arbitrary units, an index, or another manufacturer-specific scale.
Because assays use different antigens, calibration systems, thresholds, and reporting categories, a value from one laboratory cannot always be compared directly with a value from another. The clinically useful comparison is generally the result divided by that assay’s upper limit of normal. A result of 80 units may be only slightly positive in one system but strongly positive in another.
Celiac disease is different from an IgE-mediated wheat allergy, which can cause immediate hives, swelling, wheezing, vomiting, or anaphylaxis. It is also different from non-celiac gluten sensitivity, in which symptoms appear related to wheat or gluten but celiac autoantibodies and characteristic intestinal injury are absent. A tTG-IgA test is designed for celiac disease, not for diagnosing either of these other conditions.
Who Should Be Tested
Celiac disease can present with classic digestive symptoms, subtle extraintestinal problems, or no obvious symptoms at all. Clinicians may order tTG-IgA when symptoms suggest malabsorption or when another finding raises the probability of celiac disease.
Possible reasons for testing include:
- chronic or recurrent diarrhea
- abdominal bloating, pain, excessive gas, nausea, or unexplained vomiting
- weight loss or difficulty gaining weight
- iron-deficiency anemia without a clear cause or anemia that does not respond as expected to iron
- low folate, vitamin B12, vitamin D, calcium, or other nutrient deficiencies
- fatigue, weakness, mouth ulcers, headaches, or unexplained neurologic symptoms
- reduced bone density, osteopenia, osteoporosis, or fractures out of proportion to age
- delayed growth, short stature, delayed puberty, or poor weight gain in a child
- unexplained elevation of liver enzymes
- infertility or recurrent pregnancy loss when clinically appropriate causes are being assessed
- an intensely itchy blistering rash suggestive of dermatitis herpetiformis
Testing may also be considered in people at increased risk even when symptoms are mild. Risk groups include first-degree relatives of someone with celiac disease and people with type 1 diabetes, autoimmune thyroid disease, selective IgA deficiency, Down syndrome, Turner syndrome, or certain other autoimmune or genetic conditions. The decision to screen, and how often to repeat screening after an initially negative result, depends on age, symptoms, family history, associated conditions, and local guidance.
No single symptom establishes celiac disease. Bloating and fatigue are common in many disorders, while some people with substantial intestinal injury have few gastrointestinal complaints. For that reason, the value of tTG-IgA depends heavily on pretest probability—the chance of celiac disease before the blood is drawn. The same weakly positive result carries more weight in someone with chronic diarrhea, iron-deficiency anemia, and an affected parent than in someone with no symptoms or risk factors.
Dermatitis herpetiformis deserves a separate note. This intensely itchy, grouped blistering eruption often affects the elbows, knees, buttocks, back, or scalp and is a skin manifestation of gluten-sensitive disease. Celiac serology may support the evaluation, but diagnosis commonly relies on a skin biopsy from clinically normal-appearing skin next to a lesion for direct immunofluorescence. Starting a gluten-free diet before the dermatologic workup can reduce the sensitivity of both skin and blood testing.
A clinician can determine whether targeted testing or a broader celiac disease antibody panel best fits the situation.
How to Prepare for Testing
The most important preparation is dietary: the person generally needs to be eating gluten before and during the diagnostic process. Celiac antibodies can decline after gluten is removed, sometimes enough to produce a negative or borderline result despite underlying disease. Intestinal injury can also begin to heal, reducing the diagnostic yield of a biopsy.
Someone who is already avoiding gluten should not simply resume large amounts without medical advice. The amount and duration of a gluten challenge are not identical for everyone, and a challenge may be difficult or inappropriate in some medical situations. A gastroenterologist can design a supervised plan based on prior testing, current intake, symptoms, and the intended diagnostic endpoint.
Fasting is not usually required for tTG-IgA itself, although other tests drawn at the same time may require it. Medicines should not be stopped unless the prescribing clinician gives specific instructions.
Before testing, tell the clinician about:
- how much wheat, barley, or rye is currently being eaten
- when any gluten restriction began and how strict it has been
- prior celiac blood tests, biopsies, genetic tests, or a diagnosis made elsewhere
- immunosuppressive medicines or conditions that may reduce antibody production
- known selective IgA deficiency or recurrent infections
- autoimmune, liver, or inflammatory diseases that may affect interpretation
- celiac disease in close relatives
It is also useful to confirm exactly which test was ordered. “Celiac test” may refer to tTG-IgA alone, tTG-IgA with total IgA, a reflex cascade, or a multi-antibody panel. A test labeled “tTG antibody” may be IgA or IgG. These are not interchangeable.
Do not begin a lifelong gluten-free diet solely because testing was ordered or an early result appears positive. Removing gluten can make confirmation harder. A documented diagnosis supports appropriate lifelong treatment and helps prevent unnecessary restriction after a misleading result.
Understanding tTG-IgA Results
Laboratories usually classify tTG-IgA as negative, equivocal or borderline, weakly positive, or positive. The exact thresholds vary. Interpretation should therefore use the reference interval printed on the report and, when positive, the multiple of the upper limit of normal.
Negative tTG-IgA
A negative result lowers the likelihood of celiac disease when the person is eating gluten, produces normal total IgA, and has no factor that suppresses antibody production. In this setting, another diagnosis may better explain the symptoms.
A negative result is not an absolute exclusion. Seronegative celiac disease exists, although it is uncommon. False-negative results are more likely with IgA deficiency, little or no gluten exposure, mild or patchy intestinal injury, very early disease, immunosuppressive treatment, or occasionally in young children. If clinical suspicion is high, evaluation should continue rather than ending with one negative result.
Borderline or weakly positive tTG-IgA
A result near the cutoff creates more uncertainty than a strongly positive result. It may represent early celiac disease, fluctuating antibody production, assay variation, a transient or nonspecific elevation, or another condition. The next step may include repeating tTG-IgA while gluten intake continues, checking total IgA, obtaining endomysial IgA antibodies, reviewing the clinical probability, or arranging gastroenterology assessment.
Small changes around the cutoff should not automatically be interpreted as biological progression. Analytical variation can cause a result to move from just below to just above the reference threshold. Ideally, repeat testing for comparison uses the same laboratory and method.
Positive tTG-IgA
A positive result means tissue transglutaminase IgA antibodies were detected above the assay’s threshold. The higher the result relative to the upper limit of normal, the greater the probability of celiac disease in the right clinical setting. A strongly positive result accompanied by compatible symptoms and a positive endomysial antibody is much more persuasive than an isolated weak positive in a low-risk person.
“Positive” is not the same as “confirmed.” Many adults undergo upper endoscopy with duodenal biopsies while still eating gluten. Carefully selected patients may qualify for a specialist-supervised no-biopsy pathway under strict criteria.
Very high tTG-IgA
Guidelines often discuss a threshold of at least 10 times the assay’s upper limit of normal. This is not the same as a fixed value such as 100 units, because each assay has its own cutoff. For example, a result of 120 with an upper limit of 10 is 12 times the upper limit; a result of 120 with an upper limit of 30 is four times the upper limit.
A very high result substantially increases diagnostic confidence, but laboratory quality, total IgA, symptoms, and confirmatory steps still matter. Antibody concentration does not precisely measure symptom severity, villous atrophy, nutrient depletion, or future complications.
Total IgA and Related Antibody Tests
A tTG-IgA result is only dependable if the person can make IgA. Selective IgA deficiency is more common among people with celiac disease than in the general population. When IgA is very low or absent, tTG-IgA may be falsely negative because the immune system cannot produce the antibody class the assay is designed to detect.
For this reason, many clinicians order tTG-IgA and total IgA together. Some laboratories use a reflex strategy: total IgA is measured first or alongside tTG-IgA, and IgG-based tests are added when IgA is low. A separate IgA blood test can also reveal an immunoglobulin abnormality that deserves evaluation beyond celiac disease.
Related tests include:
| Test | Main role | Important limitation |
|---|---|---|
| Total IgA | Determines whether IgA-based celiac serology is interpretable | Does not detect celiac-specific antibodies |
| EMA-IgA | Highly specific confirmatory test, particularly useful after a positive or borderline tTG-IgA | Operator dependent, more time-consuming, and also unreliable in IgA deficiency |
| DGP-IgG | Alternative or additional testing in IgA deficiency and selected young children | Generally less specific than tTG-IgA in IgA-sufficient people |
| tTG-IgG | May assist when IgA deficiency is present | An isolated positive result in an IgA-sufficient person has limited specificity |
| HLA-DQ2/DQ8 | Helps exclude celiac disease in selected uncertain cases | A positive result shows susceptibility, not disease |
Endomysial antibody IgA, or EMA-IgA, detects antibodies by indirect immunofluorescence. It is highly specific but technically demanding and partly dependent on expert visual interpretation. It is often used to confirm a weak tTG-IgA result or as part of a specialist no-biopsy pathway. Some protocols require EMA-IgA positivity in a second blood sample to reduce the chance of a sample, labeling, or assay error.
Deamidated gliadin peptide antibodies are different from older antigliadin antibody tests. DGP-IgG can be useful when total IgA is deficient and may be added in selected children younger than two, depending on pediatric guidance and local practice. Ordering every available antibody indiscriminately can lower overall specificity and generate confusing isolated positives, so the panel should match the clinical question.
HLA-DQ2 and HLA-DQ8 testing has a specialized role. Absence of compatible susceptibility variants makes celiac disease very unlikely, but presence is not diagnostic because these variants are common. Testing may help when someone started a gluten-free diet before evaluation, biopsy and serology disagree, or an old diagnosis is uncertain.
What Happens After a Positive Result
A positive tTG-IgA result should trigger a structured confirmation plan rather than immediate self-treatment. The clinician first verifies the laboratory reference range, degree of elevation, total IgA, current gluten intake, symptoms, risk factors, and whether there are previous results. Referral to a gastroenterologist is common.
For many adults, the next step is upper gastrointestinal endoscopy with multiple biopsies from the duodenum, including the bulb and more distal areas. Celiac injury can be patchy, so adequate sampling matters. A pathologist looks for features such as increased intraepithelial lymphocytes, crypt hyperplasia, and villous shortening or atrophy. These changes must be interpreted with the serology and clinical context because other disorders can produce similar histology.
The person should usually continue eating gluten until the biopsy and diagnostic evaluation are complete. Starting a gluten-free diet between the blood test and endoscopy can lower antibodies and permit mucosal healing, making the results harder to interpret.
Biopsy-free diagnosis
Some children can be diagnosed without endoscopy when they meet a strict pediatric protocol, generally including a tTG-IgA level at least 10 times the upper limit of normal and confirmatory EMA-IgA in a second sample, with specialist involvement. Requirements vary by jurisdiction and guideline, and borderline or moderately positive results do not qualify.
Recent adult guidance has also introduced a conditional no-biopsy option for carefully selected adults with very high tTG-IgA, but acceptance and implementation are not uniform. Age, symptoms, assay reliability, competing diagnoses, the need to assess other upper gastrointestinal disease, and patient preference may affect the decision. A person should not assume that “10 times normal” automatically eliminates the need for endoscopy.
Other baseline evaluation
If celiac disease is confirmed, clinicians often assess the consequences of malabsorption and associated autoimmune disease. Depending on the individual, testing may include a complete blood count, iron studies, folate, vitamin B12, vitamin D, calcium, liver enzymes, thyroid function, and other nutrient measurements. Bone-density testing may be appropriate for adults with risk factors, prolonged untreated disease, fractures, or significant malabsorption. Children need attention to height, weight, growth velocity, and pubertal development.
First-degree relatives may be advised to discuss screening. One negative test does not necessarily provide lifelong exclusion if symptoms or new risk factors later appear.
False-Negative, False-Positive, and Conflicting Results
No antibody test is perfect. Apparent contradictions are resolved by checking whether the testing conditions were valid and whether the result fits the clinical picture.
Why tTG-IgA can be falsely negative
Common reasons include:
- a gluten-free or low-gluten diet before testing
- selective IgA deficiency or substantially reduced IgA
- mild, early, or patchy intestinal disease
- immunosuppressive medicines or another cause of reduced antibody production
- testing in a very young child, in whom sensitivity may be lower
- laboratory or assay variation
- rare seronegative celiac disease
When symptoms and risk are compelling, a clinician may order total IgA, IgG-based serology, EMA-IgA, HLA typing, or endoscopy despite a negative tTG-IgA. The goal is not to repeat the same test indefinitely but to identify why the expected antibody response is absent.
Why tTG-IgA can be falsely positive
Low-level tTG-IgA positivity can occur outside celiac disease, particularly in some autoimmune, inflammatory, or liver disorders. Transient positivity has also been described in certain clinical settings. Assay differences and nonspecific binding matter most near the cutoff. A false-positive result is more likely when the elevation is weak, EMA-IgA is negative, symptoms and risk factors are absent, and biopsy is normal.
A positive test should not be dismissed solely because another autoimmune disease is present; these conditions can coexist. Confirmation is more appropriate than an automatic assumption in either direction.
Positive blood test but normal biopsy
Possible explanations include early or “potential” celiac disease, inadequate or poorly oriented biopsy samples, patchy injury, reduced gluten exposure before endoscopy, a false-positive antibody, or another process. Review by an experienced gastroenterologist and pathologist may be useful. Repeat serology, HLA testing, pathology review, or later reassessment while consuming gluten may be considered.
Negative blood test but abnormal biopsy
Villous atrophy has causes other than celiac disease, including certain infections, medicines, immune disorders, and inflammatory conditions. In this situation, the clinician verifies gluten intake and total IgA, considers IgG-based tests and HLA typing, reviews medications and exposures, and investigates alternative enteropathies. A diagnosis of seronegative celiac disease should generally be made only after other causes have been evaluated.
Positive test after beginning a gluten-free diet
Antibodies do not disappear immediately, so tTG-IgA may remain positive for months after gluten withdrawal. That result can still support the previous presence of gluten-driven autoimmunity, but the diagnostic pathway may be less straightforward. The clinician may use prior records, EMA testing, HLA results, biopsy findings, and the timing and strictness of dietary change to decide whether confirmation is adequate or a supervised gluten challenge is needed.
Follow-Up After Celiac Disease Is Diagnosed
The treatment for confirmed celiac disease is a lifelong, strict gluten-free diet. Wheat, barley, and rye are avoided, while oats require attention to purity and individual tolerance. Working with a dietitian experienced in celiac disease is valuable because gluten can appear in sauces, seasonings, supplements, medicines, shared fryers, and food-preparation surfaces. The objective is not merely symptom control; it is intestinal healing and prevention of nutritional and long-term complications.
tTG-IgA is commonly repeated after diagnosis. A falling value generally supports reduced gluten exposure and an immune response to treatment. The decline is not immediate and may take longer when the starting level is very high. Children and adults can normalize at different rates.
Persistently elevated or rising tTG-IgA may indicate ongoing gluten exposure, including inadvertent cross-contact, but it is not a perfect dietary detector. The clinician should review the diet carefully, confirm that follow-up testing uses a comparable assay, assess symptoms and nutrient status, and consider other explanations. Conversely, a normal tTG-IgA does not guarantee complete mucosal healing. Some adults have persistent intestinal injury despite negative serology and improved symptoms, so repeat biopsy may be appropriate in selected cases.
Follow-up commonly includes:
- symptom and growth review
- assessment by a celiac-informed dietitian
- repeat tTG-IgA, with total IgA context when needed
- complete blood count and iron studies when anemia was present
- rechecking deficiencies such as folate, vitamin B12, vitamin D, or other nutrients
- liver tests if previously abnormal
- bone health assessment based on age and risk
- evaluation for associated autoimmune disease when clinically indicated
Persistent symptoms do not automatically mean refractory celiac disease. Hidden gluten exposure, lactose intolerance, irritable bowel syndrome, microscopic colitis, pancreatic insufficiency, and other conditions are more common. Refractory disease is rare and requires specialist evaluation.
Seek prompt medical attention for severe dehydration, repeated vomiting, black or bloody stool, fainting, rapidly worsening weakness, significant unintentional weight loss, confusion, or signs of severe anemia. A child with poor intake, lethargy, dehydration, or faltering growth should be assessed promptly. Immediate emergency care is appropriate for breathing difficulty, facial or throat swelling, or collapse after wheat exposure, because those features suggest an acute allergy rather than the slower autoimmune process measured by tTG-IgA.
The central interpretation principle is simple: tTG-IgA is an excellent first-line screening test when it is ordered in the right person, performed while gluten is being eaten, and paired with total IgA. Its value comes from the complete diagnostic context—not from a positive or negative label alone.
References
- American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease 2023 (Clinical Guideline)
- European Society for the Study of Coeliac Disease 2025 Updated Guidelines on the Diagnosis and Management of Coeliac Disease in Adults. Part 1: Diagnostic Approach 2025 (Clinical Guideline)
- Celiac Disease Tests 2021 (Official Clinical Guidance)
- Diagnosis and management of celiac disease 2025 (Clinical Review)
- Diagnostic Accuracy of IgA Anti-Transglutaminase Assessed by Chemiluminescence: A Systematic Review and Meta-Analysis 2024 (Systematic Review and Meta-Analysis)
Disclaimer
This article is for general educational purposes and does not replace evaluation by a qualified healthcare professional. Do not start or stop a gluten-free diet, perform a gluten challenge, or interpret a celiac antibody result without medical guidance. Seek urgent care for severe symptoms or signs of an acute allergic reaction.
